Cipla Limited and its wholly owned subsidiary Cipla USA Inc. , today announced the launch of Leuprolide Acetate Injection Depot 22.5mg. The product was approved by the United States Food and Drug ...
MUMBAI, India and WARREN, N.J., Nov. 29, 2022 /PRNewswire/ -- Cipla Limited (BSE: 500087) (NSE: CIPLA EQ) and its wholly owned subsidiary Cipla USA Inc. (hereafter referred to as 'Cipla'), today ...
ABBOTT PARK, Ill., March 11 /PRNewswire-FirstCall/ -- The U.S. Food and Drug Administration (FDA) has accepted for review the supplemental new drug application (sNDA ...
New Delhi, Nov 29 (PTI) Drug firm Cipla on Tuesday said it has launched Leuprolide Acetate Injection Depot 22.5 mg, used in the treatment of prostate cancer. The product was earlier approved by the US ...
ABBOTT PARK, Ill., June 20, 2011 /PRNewswire/ -- Abbott announced today that the U.S. Food and Drug Administration (FDA) has approved a new 45 mg for six-month administration formulation of Lupron ...
NEW DELHI: Drug firm Cipla on Tuesday said it has launched Leuprolide Acetate Injection Depot 22.5 mg, used in the treatment of prostate cancer. The product was earlier approved by the US Food and ...
Cipla has launched Leuprolide Acetate Injection Depot 22.5mg. The product was approved by the United States Food and Drug Administration (US FDA) based on a New Drug Application (NDA) submitted under ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback